The death rate estimates follow reports from earlier this year that found clinical cases of the drug-resistant fungus grew 95 percent from 2020 to 2021.
For the study, published June 8, CDC researchers reviewed 192 C. auris-related hospitalizations from 2017 to 2022, including 38 bloodstream infections. Hospitalizations primarily occurred among older adults, with a median age of 68. There was a high prevalence of underlying conditions and complications for patients with bloodstream and nonbloodstream C. auris, including sepsis (64 percent), diabetes (55 percent), chronic kidney disease (44 percent) and pneumonia (43 percent). The overall estimated crude mortality rate including in-hospital deaths and discharges was 34 percent.
“Our results support smaller previous investigations showing that infection and colonization with C. auris occurs most commonly in patients with complex medical conditions,” the report said.
Researchers said learning more about clinical features of patients with C. auris is critical, given the current lack of national surveillance data on clinical cases.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
